Navigation Links
Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
Date:8/1/2012

NATICK, Mass., Aug. 1, 2012 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced publication of preclinical models utilizing their proprietary SINE compounds in AML. SINEs specifically and irreversibly inhibit the nuclear transporter exportin 1 (XPO1), more commonly called CRM1 (chromosome region maintenance 1). CRM1 is the exclusive mediator of the nuclear export of p53, p73, pRb, FOXO, p21, p27, BRACA1, and other tumor suppressor proteins, along with the endogenous inhibitor of Nuclear Factor kB (NF-kB) known as IkB. Cancer cells use nuclear export of these key anti-tumor proteins to functionally inactivate them. Blockade of CRM1 with SINE leads to accumulation and activation of tumor suppressor and chemotherapy resistance proteins in the nucleus, leading to selective tumor cell apoptosis while sparing normal cells.

(Logo: http://photos.prnewswire.com/prnh/20120508/NE02031LOGO )

Romero Garzon, MD, PhD, and colleagues at the Ohio State University published a plenary paper in the journal Blood entitled, "Pre-clinical activity of a novel CRM1 inhibitor in acute myeloid leukemia" (PubMed ID: 22677130). The authors showed that Karyopharm's SINE compounds induced apoptosis at nanomolar levels in AML cell lines and in AML blasts from patients. SINEs reduced the levels of the AML oncoprotein FLT3, and when given orally to mice, prolonged their survival with good tolerability.

In the second paper, Tom Look, MD, and colleagues at the Dana Farber Cancer Institute in Boston published a paper in the journal Leukemia entitled "Anti-leukemic activity of nuclear export inhibitors that spare normal hematopoietic cells" (PubMed ID: 22847027). This paper describes the discovery of the SINE compounds based on the X-ray crystal structure of CRM1 using proprietary in silico screening methods developed by Karyopharm's fo
'/>"/>

SOURCE Karyopharm Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
2. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 1
3. United Therapeutics Corporation Reports Second Quarter 2012 Financial Results
4. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
5. United Therapeutics Corporation to Announce Second Quarter 2012 Financial Results Before Market Open on Thursday, July 26, 2012
6. Juventas Therapeutics Raises $22.2 Million Series B Financing
7. Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
8. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
9. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
10. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
11. United Therapeutics Announces Additional $100 Million Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Global Stem Cells Group subsidiary Adimarket ... biologic products for the regeneration and repair of human organs ... Cells Group’s ambitious expansion plans in Latin America, a commitment ... regenerative medicine and stem cell therapies. , Bioquark ... have the ability to alter the regulatory state of human ...
(Date:6/2/2015)... June 02, 2015 Research and Markets( ... PharmaBiotech,s new report "Biomarkers - Technologies, Markets ... This report follows the broad definition of a ... measured and evaluated as an indicator of normal ... responses to a therapeutic intervention. Tests based on ...
(Date:6/2/2015)...   Hospira, Inc. (NYSE: HSP ), ... partner, Celltrion – a global biopharmaceutical company – has received ... in Brazil – for Remsima ... in Brazil . The medication will ... biosimilar infliximab in 26 European countries and in ...
(Date:6/2/2015)... 2, 2015   Intrexon Corporation (NYSE: ... announced today the appointment of Olivier R. ... Sector.  Mr. Jarry will lead the expansion of ... applications for consumer markets.  Mr. ... experience in leading global life sciences and consumer ...
Breaking Biology Technology:Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 2Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 3Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5Intrexon Announces New Sector Leader 2Intrexon Announces New Sector Leader 3
... a development that holds much promise for the future ... of solar energy to produce clean and renewable liquid ... Lawrence Berkeley National Laboratory (Berkeley Lab) have reported a ... of the semiconductor cadmium-selenide was increased 100,000 times. ...
... , , VANCOUVER, British ... company, dedicated to the commercializing of a unique drug ... medical devices, announced today that it will present full ... catheters at the 2009 Interscience Conference on Antimicrobial Agents ...
... , GENEVA, Sept. 11 Friendly LRL ... previously-announced tender offer to acquire all of the outstanding shares ... STHK) ("Startech"), effective immediately. FLH,s offer was scheduled to ... September 30, 2009. All shares previously tendered pursuant to ...
Cached Biology Technology:Gold solution for enhancing nanocrystal electrical conductance 2Gold solution for enhancing nanocrystal electrical conductance 3Enox Biopharma Will Present Its Unique Self-Sterilizing Urinary Catheter at the 49th Annual ICAAC Meeting. 2Enox Biopharma Will Present Its Unique Self-Sterilizing Urinary Catheter at the 49th Annual ICAAC Meeting. 3Friendly LRL Holdings Terminates Offer To Acquire Startech Environmental Corporation 2Friendly LRL Holdings Terminates Offer To Acquire Startech Environmental Corporation 3
(Date:5/22/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... its promotional pricing and making the Wocket generally available for ... , Head of Marketing said, "We,ve extended the opportunity to ... of May. To get your wocket at this special price, ... store on June 1, you,ll receive a unique code that ...
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2
... -- FirstMark, the diagnostic division of GenWay ... company will be exhibiting at the inaugural Atlanta ... of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory ... provide a new, needs-based and convenient forum for ...
... Center of NYU School of Medicine will hold its ... honor three outstanding leaders in biomedical research. The Dart/NYU ... in the development of pharmaceuticals and honors those scientists ... care provided at the patient,s bedside. Recipients of this ...
... VIEW, CA (April 6, 2012) Using its ... company, has found five significant genetic associations for hypothyroidism ... conducted to date. The details of the study are ... . "With nearly 90 percent of our 125,000 ...
Cached Biology News:FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update 2NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards 2NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards 3NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards 4NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards 523andMe identifies 5 significant genetic associations for hypothyroidism 2
... The new Class II safety cabinets Heraeus HERAsafe ... and user-orientated design. ,The new frameless slanted ... work area. The new front window design makes ... The large work aperture with a height of ...
... The Jouan MSC series of ... comfortable working conditions and certification to ... automatic regulation ensures that the cabinets ... working conditions. Natural lighting, low noise ...
... a custom synthesis service for synthetic ... molecules are: Composed of 18-20 ... overhang at the 3-terminus PAGE ... and ready-to-use. Simply order your ...
... shaker stands both present the ... height, and help protect user ... tubular steel, these heavy-duty accessories ... weight and minimize the vibration ...
Biology Products: